Kangtai Biotech (300601): New product release helped improve the month-on-month improvement of products going overseas and made positive progress
Kangtai Biotech (300601): Conventional products achieve growth and steady progress overseas
Kangtai Biotech (300601): Conventional products achieve growth and steady progress overseas
Kangtai Biotech (300601): It is worth looking forward to turning the loss into sales of Yingren Diploid in 2023
Kangtai Biotech (300601): Regular vaccines are growing steadily and internationalization is progressing steadily
Kangtai Biology (300601): Conventional vaccines are growing steadily and internationalization is progressing smoothly
Kangtai Biotech (300601): Routine vaccine sales continue to gain momentum, R&D and internationalization are progressing positively
Kangtai Biotech (300601): Sales revenue of conventional vaccines increased 19% year-on-year, and commercialization of human diploid rabies vaccine is being promoted
Kangtai Biotech (300601): Rabies vaccine and chickenpox vaccine are expected to be released in the next two years; overseas expansion is accelerating
Kangtai Biotech (300601): The performance is basically in line with expectations, and the release of new products can be expected
Kangtai Biotech (300601): Regular vaccines are growing steadily, and new product releases are expected
Kangtai Biotech (300601): Signed a “Memorandum of Strategic Cooperation” with AstraZeneca to deepen overseas cooperation
Kangtai Biotech (300601): “Double improvement in quality and return” has achieved remarkable results and is optimistic about the company's long-term development
Kangtai Biotech (300601): Released the “Double Improvement of Quality and Return” plan, optimistic about the company's long-term development potential
Kangtai Biology (300601): The incentive fee is narrower than the draft, and it is expected that diploid seedlings will be released in the future
Kangtai Biotech (300601): The approval of a new vaccine motivates people to go on a journey abroad to show confidence
Kangtai Biotech (300601): Equity incentives highlight confidence, internationalization, and another city
Kangtai Biotech (300601): Human diploid rabies vaccine approved, and internationalization is progressing steadily
Kangtai Biotech (300601): Q3 performance is stable, medium and good, and going overseas to accelerate its voyage
Kangtai Biotech (300601): Performance is in line with expectations, and the internationalization process is progressing steadily
No Data